Peptide Policy Watch

How We Source

Last updated

Last updated: October 25, 2026.

Our rule is simple: if we say something happened, you can click through and see it. This page explains how we pick sources, how we date them, and what we leave out.

Primary sources first

We build posts from original documents wherever we can:

  • FDA: press announcements, the 503A bulk drug substances category list (PDF), the Category 2 safety-risk page, advisory committee pages and briefing documents, and warning letters.
  • Federal Register: official notices and rules, cited by document number and citation (for example, 91 FR 23431).
  • FTC and courts: the agency's own press release and the case page. A complaint is an allegation, not a finding.
  • SEC filings and company press releases: for what a company said about itself.
  • ClinicalTrials.gov: for what a registered study says about itself. A registry entry is not evidence that a treatment works.

Secondary sources

News outlets, law-firm client alerts and trade publications often report things before an official document is available, such as meeting vote counts. We use them only when needed, and we label them every time, for example: "reported by AJMC; not confirmed in an FDA primary document." We do not cite a secondary source as the authority for a legal or regulatory fact when a primary document exists. Anonymous-source reports are labeled as such.

Dates on everything

  • Each post lists its sources at the bottom with the URL and the date we retrieved it.
  • We say "as of [date]" for any status ("a proposal," "under review," "not yet final").
  • When a post is changed after publishing, we add an "Updated" line with the date and what changed.

What we do not cover

  • Dosing, protocols, stacking, "how to use."
  • Where to buy, vendors, product names for sale, prices of unapproved products, or links to sellers.
  • Medical advice, or claims about what "works" or is "safe."
  • Personal testimonials.
  • Anything we cannot source. If we cannot confirm it, we say we could not confirm it, or we leave it out.

We report that FDA has or has not placed a substance on a list. We do not tell readers what to do about it.

How a post is checked

Before publishing, each post is checked against a written checklist:

  1. Every factual claim has a cited source, or is labeled unverified.
  2. Dates, document numbers and names match the source.
  3. We distinguish FDA-approved drugs, compounded drugs, and unapproved products.
  4. Allegations are described as allegations.
  5. No dosing, sourcing, vendor or advice content.
  6. There is something added beyond the source, such as context or a comparison to the previous status.

Corrections

We correct errors quickly and log them publicly. See Corrections.

Who is behind this

Peptide Policy Watch is run by an independent publisher who is not a medical professional. We use AI-assisted tools to draft and the checklist above to verify. See About and Disclaimer and Disclosures.